Invesaro

Stocks Comparison

Iqvia vs Medpace: revenue, profit, margins and growth compared

Iqvia brought in $16.3B of revenue in fiscal 2025, Medpace $2.5B in fiscal 2025. Revenue changed by +5.9% at Iqvia and +20.0% at Medpace on the year before, so Medpace grew faster. Iqvia kept 8.3% of its revenue as net profit, Medpace 17.8%. Free cash flow was $2.1B at Iqvia and $681.9M at Medpace.

Side by side, latest fiscal year

IQVMEDP
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$16.3B$2.5B
Revenue growth+5.9%+20.0%
Net income$1.4B$451.1M
Net margin8.3%17.8%
Free cash flow$2.1B$681.9M
Free cash flow margin12.6%26.9%
Earnings per share (diluted)$7.84$15.28
Cash$2B$497M
Debt$15.7Bn/a
Price to earnings34.540.5
Market value$44.5B$17.3B
Dividend yieldn/an/a
Rank by revenue in sector#32 of 523 · Health care#94 of 523 · Health care

Over the years

Revenue
IQV FY2018: $10.4BIQV FY2019: $11.1BIQV FY2020: $11.4BIQV FY2021: $13.9BIQV FY2022: $14.4BIQV FY2023: $15BIQV FY2024: $15.4BIQV FY2025: $16.3BMEDP FY2018: $704.6MMEDP FY2019: $861MMEDP FY2020: $925.9MMEDP FY2021: $1.1BMEDP FY2022: $1.5BMEDP FY2023: $1.9BMEDP FY2024: $2.1BMEDP FY2025: $2.5BFY18FY19FY20FY21FY22FY23FY24FY25
IQV $16.3BMEDP $2.5B
Net income
IQV FY2018: $259MIQV FY2019: $191MIQV FY2020: $279MIQV FY2021: $966MIQV FY2022: $1.1BIQV FY2023: $1.4BIQV FY2024: $1.4BIQV FY2025: $1.4BMEDP FY2018: $73.2MMEDP FY2019: $100.4MMEDP FY2020: $145.4MMEDP FY2021: $181.8MMEDP FY2022: $245.4MMEDP FY2023: $282.8MMEDP FY2024: $404.4MMEDP FY2025: $451.1MFY18FY19FY20FY21FY22FY23FY24FY25
IQV $1.4BMEDP $451.1M
Net margin
IQV FY2018: 2.5%IQV FY2019: 1.7%IQV FY2020: 2.5%IQV FY2021: 7.0%IQV FY2022: 7.6%IQV FY2023: 9.1%IQV FY2024: 8.9%IQV FY2025: 8.3%MEDP FY2018: 10.4%MEDP FY2019: 11.7%MEDP FY2020: 15.7%MEDP FY2021: 15.9%MEDP FY2022: 16.8%MEDP FY2023: 15.0%MEDP FY2024: 19.2%MEDP FY2025: 17.8%FY18FY19FY20FY21FY22FY23FY24FY25
IQV 8.3%MEDP 17.8%
Revenue growth
IQV FY2019: +6.5%IQV FY2020: +2.4%IQV FY2021: +22.1%IQV FY2022: +3.9%IQV FY2023: +4.0%IQV FY2024: +2.8%IQV FY2025: +5.9%MEDP FY2019: +22.2%MEDP FY2020: +7.5%MEDP FY2021: +23.4%MEDP FY2022: +27.8%MEDP FY2023: +29.2%MEDP FY2024: +11.8%MEDP FY2025: +20.0%FY19FY20FY21FY22FY23FY24FY25
IQV +5.9%MEDP +20.0%
Free cash flow
IQV FY2018: $795MIQV FY2019: $835MIQV FY2020: $1.3BIQV FY2021: $2.3BIQV FY2022: $1.6BIQV FY2023: $1.5BIQV FY2024: $2.1BIQV FY2025: $2.1BMEDP FY2018: $140.6MMEDP FY2019: $184MMEDP FY2020: $227.3MMEDP FY2021: $235.1MMEDP FY2022: $351.2MMEDP FY2023: $396.7MMEDP FY2024: $572.3MMEDP FY2025: $681.9MFY18FY19FY20FY21FY22FY23FY24FY25
IQV $2.1BMEDP $681.9M

Fiscal years as each company reports them; the two may end in different months.

Questions about Iqvia and Medpace

Which is bigger by revenue, Iqvia or Medpace?

Iqvia is bigger by revenue: $16.3B in fiscal 2025, against $2.5B for Medpace in fiscal 2025.

Which keeps more of its revenue as profit, Iqvia or Medpace?

Iqvia had a net margin of 8.3% in fiscal 2025; Medpace had 17.8% in fiscal 2025.

Which grew revenue faster, Iqvia or Medpace?

In their latest fiscal years revenue changed by +5.9% at Iqvia and +20.0% at Medpace.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies